Investigational targeted oral peptide JNJ-2113 demonstrated

Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine

Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , Spring House , British Columbia , Montreal , Quebec , United States , Americans , Thompson Jr , Robert Bissonnette , Lloyd Miller , Craig Stoltz , Prnewswire Johnson , National Psoriasis Foundation , Protagonist Therapeutics Inc , Johnson Inc , Everyday Health , Exchange Commission , Neither Janssen Research Development , Janssen Biotech Inc , Janssen Research Development , Innovaderm Research , Johnson Company , Johnson , New England Journal , Psoriasis Area , Severity Index , Chief Executive Officer , Medical Director , Patient Reported Outcomes , Psoriasis Symptoms , Signs Diary , Dermatology Life Quality Index , Vice President , Immunodermatology Disease Area Leader , Protagonist Therapeutics , Janssen Biotech , Global Assessment , Body Surface Area , Plaque Psoriasis , Innovative Medicine , Private Securities Litigation Reform Act , Janssen Research , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Neither Janssen Research , Allergy Clin Immunol , Life Quality Index , Serum Samples , Inflammatory Bowel ,